EMRIS Pharma is developing a first-in-class topical solution to prevent skin toxicities caused by targeted cancer therapies such as EGFR inhibitors. These skin toxicities significantly impact cancer patients' well-being and are the major cause of discontinuation of cancer treatment. Our first product is a topical solution that addresses the skin toxicities caused by EGFR inhibitors antibodies (like cetuximab, panitumumab and amivantamab).
While current strategies focus on reducing symptoms after skin toxicity has occurred, our solution, based on a small molecule, targets the initial mechanisms of toxicity triggered by the anti-cancer therapy, offering a novel approach to prevent these skin disorders during cancer treatment.
The company is in the midst of IND-enabling studies and Phase I study is planned to start within 9 months.